Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11869258 | 0.78 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2AMAPK1PLA2G7 | |
| SCHEMBL23635695 | 0.75 | ATAD2 (0.38) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL26940380 | 0.75 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1GAAPOLBSMN1; SMN2 | |
| SCHEMBL25061759 | 0.75 | ADORA2B (0.38) | ALDH1A1MEN1KMT2APLA2G7L3MBTL1 | |
| SCHEMBL23029178 | 0.75 | KMT2A (0.50) | ALDH1A1KMT2AL3MBTL1GAAMAPT | |
| SCHEMBL3875250 | 0.75 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL8521071 | 0.74 | CYP1A2 (0.44) | ALDH1A1KMT2AL3MBTL1HAVCR2MAPT | |
| SCHEMBL2760405 | 0.73 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2AMAPK1PLA2G7 | |
| SCHEMBL11009468 | 0.73 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL3806352 | 0.72 | MAPT (0.44) | ALDH1A1MEN1KMT2AMAPK1PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61249974-A | — | — | None | — | — | JP | disclosed |
| WO-2024073709-A2 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023283434-A9 | AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE BIOCONJUGATION APPROACH | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024006953-A2 | MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023215805-A1 | ACTIN-BINDING LIM PROTEIN 3 (ABLIM3) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2023192977-A2 | SNCA-TARGETING SIRNA COMPOSITIONS FOR TREATING SNCA-ASSOCIATED DISEASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023154900-A2 | MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080096901-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2008-04-24 | — | — | US | disclosed |
| US-7226920-B2 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1678181-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005042534-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| JP-S61249974-A | NOVEL 1,3,6-TRIMETHYLURACIL DERIVATIVE | SHIYOUUN GAKUEN | 1986-11-07 | — | — | JP | disclosed |
| EP-0017706-B1 | N'-PHENYL-N-METHYLUREA DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USES AS HERBICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-08-03 | — | — | EP | disclosed |
| US-4189366-A | Radiation curable compositions containing 5-halo-6-halomethyluracil derivatives as photoinitiators | EASTMAN KODAK COMPANY (US) | 1980-02-19 | — | — | US | disclosed |
| US-4171429-A | Pyrimidine to pyrimidine transformation process | RESEARCH CORPORATION (US) | 1979-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | ALDH1A1 1178/4885MEN1 4726/4885KMT2A 1806/4885 |
| US-20080096901-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | MAP3K20, MAP3K5, MAP3K1 | ALDH1A1 4076/4885MEN1 2530/4885KMT2A 508/4885 |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | MYOF, MYO3A, MYO3B | ALDH1A1 4792/4885MEN1 2911/4885KMT2A 1685/4885 |
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALK, DGKG, EIF2AK2 | ALDH1A1 2646/4885MEN1 4197/4885KMT2A 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.